Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of EG017 in Androgen Receptor-positive, Estrogen Receptor-positive, and Human Epidermal Growth Factor Receptor-2-negative Patients With Advanced Breast Cancer.

NCT05673694 is registered in ClinicalTrials.gov with Changchun GeneScience Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05673694
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05673694 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of EG017 in Androgen Receptor-positive, Estrogen Receptor-positive, and Human Epidermal Growth Factor Receptor-2-negative Patients With Advanced Breast Cancer.
Lead sponsor
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
March 8, 2023
Completion date
January 2, 2026
Enrollment
70 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer